IL144725A0 - Novel guanidine derivatives as inhibitors of cell adhesion - Google Patents

Novel guanidine derivatives as inhibitors of cell adhesion

Info

Publication number
IL144725A0
IL144725A0 IL14472500A IL14472500A IL144725A0 IL 144725 A0 IL144725 A0 IL 144725A0 IL 14472500 A IL14472500 A IL 14472500A IL 14472500 A IL14472500 A IL 14472500A IL 144725 A0 IL144725 A0 IL 144725A0
Authority
IL
Israel
Prior art keywords
inhibitors
formula
cell adhesion
compounds
guanidine derivatives
Prior art date
Application number
IL14472500A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL144725A0 publication Critical patent/IL144725A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14472500A 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion IL144725A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99102916A EP1028114A1 (en) 1999-02-13 1999-02-13 Novel guanidine derivatives as inhibitors of cell adhesion
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
IL144725A0 true IL144725A0 (en) 2002-06-30

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14472500A IL144725A0 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Country Status (11)

Country Link
US (1) US6340679B1 (xx)
EP (2) EP1028114A1 (xx)
JP (1) JP4642242B2 (xx)
AT (1) ATE273285T1 (xx)
AU (1) AU768206B2 (xx)
CA (1) CA2371789C (xx)
DE (1) DE60012890T2 (xx)
ES (1) ES2225086T3 (xx)
IL (1) IL144725A0 (xx)
MX (1) MXPA01008072A (xx)
WO (1) WO2000047564A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
CN1377268A (zh) 1999-08-13 2002-10-30 比奥根公司 细胞粘合抑制剂
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
PL1682537T3 (pl) * 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
EP3797775A1 (en) 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
BR9508178A (pt) 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
EP0762882A4 (en) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
CA2227265C (en) 1995-08-14 2012-01-03 The Scripps Research Institute Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
SK176898A3 (en) * 1996-06-28 1999-05-07 Merck Patent Gmbh Phenylalamine derivatives as integrin inhibitors
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
KR20010034319A (ko) 1998-01-23 2001-04-25 아벤티스 파마 도이칠란트 게엠베하 골흡수의 억제제 및 세포유착의 억제제로서 신규한술폰아미드 유도체

Also Published As

Publication number Publication date
WO2000047564A1 (en) 2000-08-17
CA2371789A1 (en) 2000-08-17
JP2002536438A (ja) 2002-10-29
MXPA01008072A (es) 2002-07-30
CA2371789C (en) 2009-04-14
EP1028114A1 (en) 2000-08-16
AU768206B2 (en) 2003-12-04
DE60012890D1 (de) 2004-09-16
EP1155003A1 (en) 2001-11-21
ES2225086T3 (es) 2005-03-16
ATE273285T1 (de) 2004-08-15
US6340679B1 (en) 2002-01-22
JP4642242B2 (ja) 2011-03-02
DE60012890T2 (de) 2005-08-25
AU2669900A (en) 2000-08-29
EP1155003B1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
IL144725A0 (en) Novel guanidine derivatives as inhibitors of cell adhesion
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
IL217446A (en) Pharmaceutical preparation containing a highly purified active ingredient of 7 - chloro - 5 - hydroxy - 1 - [2 - methyl - 4 - (2 - methylbenzoyl - amino) benzoyl] - 2, 3, 4, 5 - tetrahydro - h - 1 - Benzazepine has a purity of more than 99.5% or its salt, or a drug of its salt
EP1076055A4 (en) 1- (1-SUBSTITUTED-4-PIPERIDINYL) METHYL] -4-PIPERIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATES THEREOF
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
WO2004060376A8 (en) The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
MY133246A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
UA72923C2 (uk) Заміщені похідні пурину як інгібітори клітинної адгезії
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HK1041000A1 (en) Novel pyrimidine derivatives and processes for thepreparation thereof.
EP1179342A4 (en) IMMEDIATE RELEASE MEDICINAL COMPOSITIONS FOR ORAL ADMINISTRATION
AU2674201A (en) Thienylalanine derivatives as inhibitors of cell adhesion
AU2001278503A1 (en) Novel guanidino derivatives as inhibitors of cell adhesion
MXPA04002784A (es) Sales farmaceuticamente aceptables de 20(s)-camptotecinas.
AR030874A1 (es) Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso
IL173476A0 (en) 8-chloro-2,3-benzodiazepine derivatives
WO2004082587A3 (en) Stable lamotrigine pharmaceutical compositions and processes for their preparation
CA2379086A1 (en) 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
TH65078A (th) อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล